Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 4, pp. 641-648
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 168
Cardiovascular complications of COVID-19
Farnaz Farshidfar, Navid Koleini, Hossein Ardehali
JCI Insight (2021) Vol. 6, Iss. 13
Open Access | Times Cited: 131
Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19
Farzan Vahedifard, Krishnan Chakravarthy
Emergent Materials (2021) Vol. 4, Iss. 1, pp. 75-99
Open Access | Times Cited: 111
Hematological Abnormalities in COVID-19: A Narrative Review
Asma Rahman, Roshan Niloofa, Umesh Jayarajah, et al.
American Journal of Tropical Medicine and Hygiene (2021) Vol. 104, Iss. 4, pp. 1188-1201
Open Access | Times Cited: 106
Remdesivir for COVID-19: challenges of underpowered studies
John Norrie
The Lancet (2020) Vol. 395, Iss. 10236, pp. 1525-1527
Open Access | Times Cited: 124
A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment
Ramiro Picoli Nippes, Paula Derksen Macruz, Gabriela Nascimento da Silva, et al.
Process Safety and Environmental Protection (2021) Vol. 152, pp. 568-582
Open Access | Times Cited: 89
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Omkar Indari, Shweta Jakhmola, E. Manivannan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 86
Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective
Choongho Lee, Won Jun Choi
Archives of Pharmacal Research (2021) Vol. 44, Iss. 1, pp. 99-116
Open Access | Times Cited: 83
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance
Dhanapalan Aiswarya, Venkatesh Arumugam, Thanigachalam Dineshkumar, et al.
Kidney International Reports (2020) Vol. 6, Iss. 3, pp. 586-593
Open Access | Times Cited: 82
Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
Vivek P. Chavda, Md. Mer Mosharraf Hossain, Jayesh Beladiya, et al.
Biologics (2021) Vol. 1, Iss. 3, pp. 337-356
Open Access | Times Cited: 77
Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database
Vaishali Gupte, Rashmi S. Hegde, Sandesh Sawant, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 61
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 60
A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19
Srikanth Umakanthan, Vijay Kumar Chattu, Anu Vinod Ranade, et al.
AIMS Public Health (2021) Vol. 8, Iss. 1, pp. 137-153
Open Access | Times Cited: 55
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Partha Biswas, Mohammad Mehedi Hasan, Dipta Dey, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 42, pp. 59570-59593
Open Access | Times Cited: 55
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
Donglan Liu, Chunke Chen, Dingbin Chen, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 4
Open Access | Times Cited: 21
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications
Jaykaran Charan, Rimple Jeet Kaur, Pankaj Bhardwaj, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 14, Iss. 1, pp. 95-103
Open Access | Times Cited: 66
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
Abdullahi Rabiu Abubakar, Ibrahim Sani, Brian Godman, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 4673-4695
Open Access | Times Cited: 61
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”
Dr Subodh Kumar Pathak, Dr Abhijeet Ashok Salunke, Praveen Thivari, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 6, pp. 1673-1680
Open Access | Times Cited: 51
Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures
Martina Zafferani, Christina Haddad, Le Luo, et al.
Science Advances (2021) Vol. 7, Iss. 48
Open Access | Times Cited: 46
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2
Devendra Singh Negi, Irshad Ahmad
European Journal of Medicinal Chemistry (2021) Vol. 213, pp. 113157-113157
Open Access | Times Cited: 45
The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
Hao Shen, Nu Zhang, Yuqing Liu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 32
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112700-112700
Open Access | Times Cited: 27
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Cristina Cerqueira Vieira, Lucas Nery, Ludimila de Barcelos Ubaldo Martins, et al.
Current Drug Targets (2020) Vol. 22, Iss. 3, pp. 254-281
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top